EULAR 2008 Highlights
The Annual European Congress of Rheumatology was held in Paris, France from June 11-14, 2008. This is the official meeting of the European League Against Rheumatism (EULAR). Full abstract reports may be can be found online by visiting the EULAR Congress website. While it is not possible to review all of the important findings from these meetings, some selected highlights are summarized. These highlights focus on Rheumatoid Arthritis. The highlights are summarized by Joan Bathon, M.D. and Jon Giles, M.D.
Rheumatoid Arthritis : Anti-B-Cell Therapy
- OP-0123 The Effects of Repeated Doses of Briobacept (BR3-FC) in Patients with Rheumatoid Arthritis
- OP-0134 Combination Rituximab and Leflunomide Produces Lasting Responses in Rheumatoid Arthritis
- OP-0250 The Safety and Efficacy of Ocrelizumab; a Humanized anti-CD20 Antibody Administered as a Single Infusion Regimen to Patients with Active Rheumatoid Arthritis
- OP-0252 Repeated Therapy with TRU-015 is Well Tolerated and Results in Consistent Pharmacodynamic Effects in Rheumatoid Arthritis Patients
- OP-0253 A Single Course of Rituximab does not Abrogate Anti-Infliximab Antibodies in Patients with Rheumatoid Arthritis
Rheumatoid Arthritis : Anti-IL6 Therapy
- OP-0131 Tocilizumab Monotherapy is Superior to Methotrexate Monotherapy in Reducing Disease Activity in Patients with Rheumatoid Arthritis: The AMBITION Study
- OP-0251 Tocilizumab Significantly Improves Disease Outcomes in Patients with Rheumatoid Arthritis Whose Anti-TNF Therapy Failed: the RADIATE Study
Rheumatoid Arthritis : Anti-T-Cell Therapy
Rheumatoid Arthritis : Anti-TNF Therapy
- LB-0001 In Patients with Early RA who Failed Initial MTX, the Addition of Anti-TNF Yields Better EULAR and ACR Responses than the Additional of Conventional DMARDs: 1-Year Results of the SWEFOT Clinical Trial
- OP-0121 Safety, Local Tolerability and Clinical Response after Intra-Articular Administration of a Recombinant Adeno-Associated Vector Containing a TNF Antagonist Gene in Inflammatory Arthritis
Rheumatoid Arthritis : Clinical Aspects
- OP-0040 Drug-Free Remission after Treatment Discontinuation Following One Year of Methotrexate or Placebo Treatment in Undifferentiated Arthritis Patients
- OP-0137 Does Inflammation and Immune-Suppressive Treatment Affect Survival from Cancer? A Nation-Wide Population Based Study on Cancer Survival in Patients with RA in Sweden 1999-2006
- OP-0138 Risk of Active Tuberculosis among Biologic-Naïve RA Patients: Retrospective Cohort Study in a U.S. Claims Database
- OP-0139 Influence of Gender on Assessments of Disease Activity and Function in Rheumatoid Arthritis in Relation to Radiologic Damage Over the First Five Years of Disease
- OP-0144 Which Patients Stop Working Because of RA? Results from an Inception Cohort with 10 Yr Follow-up
Rheumatoid Arthritis : DMARD Therapy
- OP-0043 In Early RA, Patients with a Good Initial Response to MTX Monotherapy Continue to Have Excellent Clinical Outcomes during the First Year of Therapy
- OP-0045 Methotrexate (MTX) and Sulfasalazine (SSZ) Therapy in DMARD Naïve Patients with Early RA in a Real Life Setting: Comparison of Baseline Characteristics and Response Rates
Rheumatoid Arthritis : Other
- OP-0041 A 3 Week Course of IM Steroid Injections May Prevent the Progression of Very Early Inflammatory Polyarthritis: Results of the STIVEA Trial
- OP-0042 New Modified-Release Prednisone Tablet Shows Sustained Reduction of Morning Stiffness and Interleukin-6 in Patients with Rheumatoid Arthritis
- OP-0044 Initial Efficacy of INCB018424, a Selective Janus Kinase 1&2 (JAK 1&2) Inhibitor in Rheumatoid Arthritis (RA)
- OP-0122 Preliminary Safety and Efficacy of Baminercept Alfa (BG9924, LTBR-IG) in the Treatment of Rheumatoid Arthritis (RA)
- OP-0124 ARRY-162, A Novel Inhibitor of MEK Kinase: Phase 1A-1B Pharmacokinetic and Pharmacodynamic Results